Table 1 Synergistic 2-agent combinations
From: Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials
Agent 1 | Agent 2 | Standard of care* | Expected ORR 1 | Observed ORR 0 | p synergy | Cancer subtype |
|---|---|---|---|---|---|---|
Docetaxel | Doxorubicin | Yes | 40 | 65 | 7.70E-43 | Breast cancer |
Oxaliplatin | 5-fluorouracil | Yes | 25 | 52 | 1.82E-17 | Colorectal, gastric cancer |
Irinotecan | Etoposide | No | 19 | 66 | 4.98E-13 | Lung cancer |
Doxorubicin | Ifosfamide | Yes | 19 | 48 | 1.20E-09 | Gynecologic, soft tissue sarcoma |
Bortezomib | Thalidomide | Yes | 56 | 100 | 2.13E-09 | Myeloma |
Capecitabine | Irinotecan | No | 35 | 48 | 9.53E-09 | Colorectal, gastric, lung cancer |
S-1 | Irinotecan | No | 33 | 47 | 1.20E-07 | Colorectal, gastric, lung cancer |
Oxaliplatin | Doxorubicin | No | 27 | 68 | 1.30E-07 | Ovarian cancer |
Oxaliplatin | Irinotecan | Yes | 24 | 52 | 4.30E-06 | Colorectal, lung cancer |
Capecitabine | Radiation | No | 65 | 88 | 3.11E-05 | Cervical cancer |
Rituximab | Alpha-interferon | No | 67 | 94 | 2.48E-04 | Lymphoma |
Oxaliplatin | Capecitabine | Yes | 38 | 44 | 3.41E-03 | Colorectal, gastric cancer |
5-fluorouracil | Irinotecan | Yes | 22 | 38 | 5.87E-03 | Colorectal cancer |
Capecitabine | Alpha-interferon | No | 38 | 54 | 3.34E-02 | Renal cancer |
Fludarabine | Thalidomide | No | 78 | 100 | 4.05E-02 | Leukemia |